RNAi treatment has been shown to successfully modify human-related target gene expression, including cancer. It has the capacity to control non-standard oncogenes, such as oncogenic lncRNAs

Abstract

Recent breakthroughs in clinical research and deployment of RNAi therapeutics have validated siRNA's promise to cure human diseases. RNAi therapy has been proven to effectively alter the expression of human-related target genes, including cancer. It has the potential to regulate oncogenes not addressed by standard treatment, such as oncogenic lncRNAs, to treat cancer more successfully. Due to their intrinsic liver affinity, successful RNAi therapies in clinical development primarily target liver diseases. Systemic dispersion of therapeutic siRNAs is an effective cancer therapy technique, especially for advanced diseases. Despite recent advances in siRNA delivery technologies, a problem remains with efficiently distributing siRNAs into solid tumors and cancer cells. To overcome several challenges to the dispersion of siRNA in cancer cells' cytoplasm, novel and highly effective delivery systems need to be devised. Delivery devices' ability to sense and adjust to environmental changes throughout the delivery process can make cytosolic distribution into cancer cells more efficient and accurate. Due to their well-defined and simple chemical structures and their multifunctionalities to respond to environmental changes to facilitate efficient cytosolic transport, environment-responsive lipids are promising platforms for clinical development to deliver siRNA. The primary benefit of simple, well-defined lipid structures over complex systems for cost-effective CMC and clinical translation is the simple, well-defined lipid structures. Environment-responsive lipids might be considered as simple, clever siRNA delivery methods that can overcome delivery difficulties for successful cancer treatment.